UV Blood Irradiation for Health & Longevity

Evidence Review created on 10/30/2026 using AI4L / Opus 5.5

Also known as: Ultraviolet Blood Irradiation, UBI, UVBI, Ultraviolet Blood Irradiation Therapy, Ultraviolet Irradiation of Blood, Knott Technique, Hemo-Irradiation, Photoluminescence Therapy, Photo-Oxidation Therapy, Photohemotherapy, Intravenous Ultraviolet Light Therapy

Motivation

Ultraviolet blood irradiation is a procedure in which a small portion of a person’s own blood is exposed to ultraviolet light and returned to the circulation, either by passing drawn blood through a light chamber or by shining light into a vein through a thin fiber. It attracts interest as a drug-free way to influence the immune system, with proponents citing infection control, circulation and resilience.

The method was developed in the United States in the late 1920s and was used in hospitals for serious infections before antibiotics became widespread. Research then moved mainly to Russia and Germany, and the procedure has recently reappeared in wellness clinics, where it is offered for a wide range of complaints and for healthy aging. Renewed interest rests on one idea: that a brief light-induced stress to a small fraction of the blood might prompt a wider response throughout the body.

This review examines what human studies show about the benefits and risks of ultraviolet blood irradiation, how strong that evidence is, and what the procedure involves, focusing on health-conscious adults weighing it for long-term health rather than a diagnosed disease.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Blood irradiation therapy

Grokipedia’s article covers ultraviolet and laser blood irradiation from Knott’s first patient to modern intravenous devices, with sections on clinical studies, adverse effects and regulatory controversy.

Examine

No Examine article on UV blood irradiation exists.

ConsumerLab

No ConsumerLab article on UV blood irradiation exists.

Systematic Reviews

No systematic reviews or meta-analyses for UV Blood Irradiation were found on PubMed as of 10/30/2026.

Neither the claimed benefits nor the principal risks (procedure-related harm and bloodborne infection) of UV blood irradiation are represented by a systematic review or meta-analysis.

Mechanism of Action

In the classic method, about 5–7% of blood volume is withdrawn, anticoagulated (treated with a drug that prevents clotting), passed for about 10 seconds under short-wave ultraviolet light (UVC, 253.7 nm) and reinfused, per a review (Hamblin 2017). Newer devices shine long-wave ultraviolet (UVA) and visible light into a vein through a fiber.

Not direct sterilization: the dose and volume are too small to kill most circulating microbes, so the effect lies in blood cells, a review notes (Wu 2016).
Phagocyte activation: low doses raise the activity of phagocytes (white cells that engulf microbes) and their output of reactive oxygen species (ROS, reactive oxygen molecules) and nitric oxide.
Lymphocyte suppression: medium-wave (UVB) and UVC light damage the DNA (genetic material) of lymphocytes (immune white cells) and kill most exposed T cells (a lymphocyte type) within 48–72 hours, possibly dampening inflammation.
Brief oxidative stress: a short oxidant burst may up-regulate antioxidant defenses, a hormetic (brief beneficial stress) pattern.
Lipid and protein oxidation: ultraviolet light oxidizes blood lipids, per a review (Hamblin 2017), and albumin (the main blood protein) (Sozarukova 2023), which may signal or harm.

A competing explanation: laboratory changes in a few percent of the blood may lack clinical relevance, and reported improvements may reflect natural recovery, a view from a university outreach office with no financial stake (McGill Office for Science and Society article). In a laboratory test of a multi-wavelength intravenous device, bacteria fell only slightly, from red rather than ultraviolet light (Willmott 2023).

Historical Context & Evolution

UV blood irradiation began as an infection treatment: Seattle inventor Emmett Knott, reasoning from ultraviolet skin therapy, built a blood irradiation chamber, later describing its development (Knott 1948); a review dates his first patient, with streptococcal sepsis (bloodstream infection), to 1928 (Hamblin 2017). Through the 1940s, George Miley, E. W. Rebbeck and others published uncontrolled series in sepsis, typhoid and other infections (Miley 1947; Rebbeck 1949), which that review summarizes as reporting rapid recovery.

In 1952 a team reporting on 68 patients, many with liver infection, concluded that none benefited and noted that patients felt better whether or not their drawn blood was irradiated (Schwartz 1952), as quoted by McGill’s Office for Science and Society. Its full text was inaccessible for this review; advocates call the study biased, but no published reanalysis supports or refutes that claim. Antibiotics and the polio vaccine then displaced it in Western hospitals, while Soviet and German clinicians kept studying it, sometimes combined with oxygen (Steinbart 1956).

Health-optimization interest grew from the idea that a brief stress could reset immune function. In the 2000s the device maker Vasogen tested a related blood-exposure method in heart failure; its large trial missed its main goal (Torre-Amione 2008). Wellness clinics now offer it for chronic infection, fatigue and resilience; in 2025 the US Food and Drug Administration (FDA) warned a maker of unapproved UV and ozone blood-treatment devices (FDA warning letter).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the controlled human trials are single, small, unblinded trials per condition, mostly available only as English abstracts of Russian reports, and no outcome has been replicated by independent groups in the same condition.

Medium 🟩 🟩

Faster Clearance of Bacterial Infections When Added to Antibiotics

Randomized trials from three separate Russian groups added UVBI to standard antibiotic treatment: Shurygin in children with pulmonary tuberculosis, Kuvshinchikova in chronic obstructive bronchitis (long-term airway inflammation with airflow limitation) with bacterial complications, and Potashov in erysipelas (a streptococcal skin infection). Each reported faster symptom or bacterial clearance than antibiotics alone. Each tested a different infection, and the reports give no blinding details. For a healthy adult, relevance is limited to recovery from an acute infection.

Magnitude: Cessation of bacterial shedding was about twice as frequent with UVBI as with standard therapy alone in tuberculosis (Shurygin 2009); sputum pathogen growth fell 10-fold with UVBI plus antibiotics in bronchitis, control figure not reported, not compared between groups (Kuvshinchikova 1998); neither abstract reports a confidence interval. The erysipelas trial reported fewer complications and recurrences without figures in its abstract (Potashov 1992).

Low 🟩

Lower Viral Load in Chronic Hepatitis C

Nine patients given 15 UVBI sessions had a modest fall in hepatitis C virus (HCV) load; authors included device maker AVIcure Bioscience (Kuenstner). A 1952 series of 68 patients, many with liver infection, reported no benefit but predates HCV identification and measured no viral load (Schwartz 1952). Evidence is uncontrolled.

Magnitude: Mean HCV load fell 21.5% by study end and 44.9% at the day-259 low point, no control group (Kuenstner 2015).

Longer Walking Distance in Intermittent Claudication

A blinded randomized trial of Vasogen’s immune modulation therapy (IMT: blood exposed to UV light, ozone and heat, injected into muscle) lengthened pain-free walking in claudication (leg pain from narrowed arteries) (McGrath). Mismatch: combined exposures, route. Höfs measured only limb blood flow, unchanged in five UVBI-treated patients.

Magnitude: Median initial claudication distance rose 81% with IMT vs 44% with placebo at 24 weeks; responders 65% vs 41% (p=0.06, just short of statistical significance) (McGrath 2002); no effect on limb blood flow in five patients, no control group (Höfs 1988).

Fewer Heart Failure Events ⚠️ Conflicted

A 75-patient pilot of Vasogen’s IMT reported fewer deaths and hospitalizations, but the 2,426-patient ACCLAIM trial by the same Vasogen-sponsored group found no significant effect on its main outcome. Mismatch: combined exposures, intramuscular route. Net: the larger, stronger trial was null.

Magnitude: Death or cardiovascular hospitalization occurred in 399 IMT vs 429 placebo patients, hazard ratio (HR, relative risk over time) 0.92, 95% confidence interval (CI, range of plausible values) 0.80–1.05 (Torre-Amione 2008); the pilot reported lower risk without effect sizes in its abstract (Torre-Amione 2005).

Speculative 🟨

Immune Recalibration and Antioxidant Up-Regulation

Laboratory studies show UV-exposed blood raises phagocyte activity; in rabbits it raised antioxidant enzymes, a proposed brief-stress effect, as summarized in a review (Hamblin 2017). The basis is mechanistic and animal only.

Benefit-Modifying Factors

Genetic polymorphisms: No genetic variant has been studied for its effect on response to UV blood irradiation; any claimed genotype-based benefit selection lacks evidence.
Baseline biomarkers: In laboratory work, phagocyte activity rose more from a low starting level, and lipid peroxidation (oxidative damage to fats) fell when high but rose when low, per a review (Hamblin 2017).
Sex: No study has compared benefit between men and women; the weight-based Knott dose (about 3.5 mL/kg) automatically scales the volume treated to body size.
Pre-existing conditions: All controlled benefit signals come from people with active infection or arterial or heart disease; no trial has tested benefit in healthy adults seeking longevity, so the expected gain for that group is unknown.
Age: No age-stratified outcome data exist; in lymphocytes from donors aged 17–74, DNA repair after UVC exposure did not differ by age, as summarized in a review (Hamblin 2017), giving no mechanistic reason to expect a different response in older adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse events of UV blood irradiation itself have never been collected systematically in controlled trials, and the infection-transmission evidence comes from outbreak investigations of related autologous (own-blood) procedures.

Medium 🟥 🟥

Bloodborne Infection From Unsafe Blood Handling

Procedures that withdraw, handle and reinfuse a person’s own blood can transmit hepatitis viruses when equipment or multi-dose solutions are reused. Two independent outbreak investigations document this for related autologous blood therapies: hepatitis B at a UK alternative medicine clinic (Webster) and hepatitis C after ozone-enriched autologous blood reinfusion in Rome (Faustini). Neither used ultraviolet light; the shared delivery vehicle is extracorporeal (outside-the-body) blood handling, so the gap is the payload. The harm can be lifelong.

Magnitude: HCV infection in 19.4% of the 31 exposed patients tested vs an estimated 0.9% in the regional population (Faustini 2005); hepatitis B exposure markers in 57 of 356 (16%) tested patients and staff, no control group (Webster 2000).

Low 🟥

Venipuncture Reactions: Bruising, Fainting and Vein Inflammation

Bruising, arm pain and vasovagal reactions (a reflex fall in heart rate and blood pressure that can cause fainting) follow blood withdrawal, per a donor review (Newman); intravenous lines often cause phlebitis (vein inflammation), per a meta-analysis (Marsh). Evidence is uncontrolled and indirect: donation draws more blood; catheters stayed days.

Magnitude: Bruise 23%, sore arm 10% and vasovagal reaction 7% after whole-blood donation, as reported in a review, no control group (Newman 2004); phlebitis in 19.3% of peripheral intravenous catheters, pooled in a meta-analysis, no control group (Marsh 2020).

Delayed Effective Treatment of Serious Disease

UVBI is marketed for infections, cancer and chronic illness, creating a risk that it replaces proven care. Evidence is indirect: alternative medicine used alone for curable cancer carried higher mortality (Johnson); UVBI itself was not studied.

Magnitude: Risk of death 2.5 times higher with alternative medicine alone than with conventional treatment, HR 2.50 (95% CI 1.88–3.27); five-year survival 54.7% vs 78.3% in the matched cohort (Johnson 2018).

Many set-ups anticoagulate drawn blood with heparin, whose label lists bleeding and heparin-induced thrombocytopenia (HIT, an immune platelet drop with clotting risk) (heparin FDA label). Evidence is indirect: multi-day preventive dosing, not brief procedural doses.

Magnitude: HIT in 2.6% with unfractionated (standard) heparin vs 0.2% with low-molecular-weight heparin (a smaller-molecule form) during multi-day prevention dosing, per a meta-analysis (Martel 2005); no rate exists for single procedural doses.

Flare of Systemic Lupus Erythematosus

A case report describes exacerbation of systemic lupus erythematosus (an autoimmune disease that ultraviolet light can worsen) during reinfusion of UV-irradiated blood (Reznikova). The mechanism is unknown; sunlight is a recognized trigger of lupus flares. Evidence is a single uncontrolled case report.

Magnitude: Not quantified in available studies. Only a single case report exists, so no rate or comparison group is available (Reznikova 1986).

Speculative 🟨

Oxidative Damage to Blood Proteins, Lipids and Lymphocytes

Ultraviolet light oxidizes albumin and blood lipids and damages lymphocyte DNA in laboratory studies (Sozarukova 2023; review: Hamblin 2017), raising unstudied concern about cumulative effects of repeated sessions. Basis is laboratory only.

Risk-Modifying Factors

Genetic polymorphisms: G6PD deficiency (an inherited lack of an enzyme that protects red cells from oxidants) may raise the risk of oxidant-induced hemolysis (red cell breakdown); this is inferred from mechanism, with no UVBI data.
Baseline biomarkers: Low hemoglobin limits tolerance of repeated blood draws, and a low or falling platelet count is a warning sign for HIT when heparin is used, per a meta-analysis (Martel 2005).
Sex: Female sex, younger age, smaller blood volume and lower blood pressure each raise vasovagal reaction risk during blood withdrawal, per a meta-analysis (Wu 2025).
Pre-existing conditions: Bleeding disorders, anticoagulant therapy (drugs slowing clotting), heart failure, porphyria (inherited disorders causing light sensitivity) and lupus increase procedural or photosensitivity risk; infection-prone or immunosuppressed people face greater harm from contaminated equipment.
Age: Younger and first-time participants have more vasovagal reactions during blood withdrawal, per a meta-analysis (Wu 2025); older adults have more fragile veins and more anticoagulant use, raising bruising and bleeding risk.

Key Interactions & Contraindications

Documented interactions:

Anticoagulants and antiplatelet drugs (drugs slowing clotting: warfarin, apixaban, rivaroxaban, clopidogrel): With procedural heparin they may induce bleeding (heparin FDA label); consequence: hematoma (blood pooling under skin). Mitigation: disclosure to the practitioner, a citrate-only protocol, and prolonged pressure on the site.
Over-the-counter antiplatelet analgesics (pain relievers that also slow clotting: aspirin, ibuprofen, naproxen): Covered by the heparin label warning on drugs affecting platelet aggregation (heparin FDA label); consequence: additive bleeding at the access site. Mitigation: no same-day use where medically acceptable.
Psoralens (light-activated drugs: methoxsalen): Photoactivated methoxsalen cross-links DNA in extracorporeally treated white cells, the basis of photopheresis (psoralen-plus-UVA treatment of separated white cells) (UVADEX FDA label); consequence: immune-suppressing lymphocyte damage from UVA devices. Mitigation: no concurrent use outside a specialist photopheresis service.

Theoretical interactions (inferred from mechanism, not studied in humans):

Photosensitizing drugs (drugs making tissue light-reactive: doxycycline, ciprofloxacin, amiodarone, hydrochlorothiazide, fenofibrate): Ultraviolet light could activate them in blood; red cells loaded with fenofibrate underwent ultraviolet-induced hemolysis in a laboratory test (Eberlein-König 1997). Consequence: phototoxic red cell breakdown. Mitigation: medication review before sessions.
Photosensitizing supplements (St. John’s wort): Its pigment hypericin is a photosensitizer, inferred to add phototoxic risk to irradiated blood. Mitigation: a pause before sessions.
High-dose antioxidant supplements (vitamin C, vitamin E): Alpha-tocopherol (vitamin E) blocked ultraviolet-induced oxidant production by neutrophils (the most common white cell) in laboratory work, per a review (Hamblin 2017), inferred to blunt the proposed oxidative signal. Mitigation: no large doses near sessions.
Bleeding-prone supplements (fish oil, ginkgo, high-dose vitamin E): Additive antiplatelet effect with procedural heparin, inferred from mechanism; consequence: bruising. Mitigation: disclosure to the practitioner.
Immunosuppressive drugs (drugs that dampen the immune system: tacrolimus, cyclosporine, prednisone): UVBI kills lymphocytes and alters immune signaling; consequence: unpredictable immune suppression, risking infection or loss of disease or transplant control. Mitigation: coordination with the prescribing specialist.
Ozone blood treatment or high-dose intravenous vitamin C in the same session: Additive oxidative load on red cells, inferred from shared oxidant mechanism; consequence: hemolysis or methemoglobinemia (oxygen-carrying failure of hemoglobin). Mitigation: no stacking of oxidative therapies.

Populations who should avoid UV Blood Irradiation:

People with a history of heparin-induced thrombocytopenia, or with heparin or pork hypersensitivity, when heparin is used: labeled contraindications (heparin FDA label).
People using UVBI in place of established treatment for curable cancer or serious infection: human evidence of excess mortality with substituted alternative care (Johnson 2018).
People with systemic lupus erythematosus: human evidence of disease exacerbation during reinfusion of UV-irradiated blood (Reznikova 1986).
People with porphyria: inferred from porphyrin-driven photosensitivity; no human UVBI data.
People with G6PD deficiency: inferred from oxidant-triggered hemolysis; no human UVBI data.
Pregnant people: inferred from the absence of any safety data and fetal vulnerability to maternal fainting and blood loss; no human UVBI data.
People with severe anemia or active bleeding disorders: inferred from blood withdrawal and anticoagulant exposure; no human UVBI data.

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

Sterile single-use kits: New tubing, cuvettes and saline for every session prevent the hepatitis transmission documented with reused autologous blood equipment (Webster 2000).
Licensed clinical setting: Physician supervision, resuscitation equipment and staff trained in blood drawing reduce the risk of mishandled blood, infection and unmanaged fainting.
Fluids and salty snack beforehand: Water and a salty snack before the draw cut vasovagal reactions by about 15% in a blood donor program (Lewin 2023).
Reclined position and slow first session: Lying back during and 10–15 minutes after the first sessions prevents injury from fainting.
Weight-based volume cap: A withdrawn volume near the historical 3.5 mL/kg, per a review (Hamblin 2017), avoids the excess exposure and loss of benefit Knott reported above that level.
Medication and supplement review: Screening for photosensitizers, psoralens and anticoagulants at least 7 days before the first session prevents phototoxic red cell damage and bleeding.
Platelet check with repeated heparin: Baseline and in-course platelet counts detect HIT; heparin stops if platelets fall by 50% or below 100 × 10⁹/L, the platelet criterion (plus a positive HIT test) of a meta-analysis’s HIT definition (Martel 2005).
No substitution for proven care: Using UVBI only alongside, never instead of, established treatment for a diagnosed disease prevents the excess mortality linked to substituted care (Johnson 2018).

Therapeutic Protocol

Each dose below is cited to its source; other parameters (timing, session spacing, cycling) reflect common practice. No protocol has been tested for healthy adults seeking longevity.

Extracorporeal Knott method (UVC): About 3.5 mL/kg (5–7% of blood volume), citrated, exposed for about 10 seconds at 253.7 nm and reinfused immediately, per a review (Hamblin 2017); popularized by Emmett Knott and George Miley.
Volume per session: Historical draws were 250–300 mL, about 6% of a 5-liter blood volume (Science-Based Medicine critique).
Trial regimen: 15 sessions over 22 weeks with the AVIcure Hemo-modulator, a modified Knott device, in the hepatitis C trial (Kuenstner 2015).
Intravenous catheter devices: A fiber-optic cable placed in a vein irradiates blood with ultraviolet light for about one hour per session, per the maker UVLrx (MedCity News report).
Ultraviolet plus oxygen (Wehrli method): A German variant combining blood irradiation with oxygenation (Steinbart 1956).
Session spacing: Clinics commonly give one to three sessions per week for a short course; no comparison of schedules exists.
Best time of day: No data; daytime sessions after a meal and fluids lower fainting risk.
Half-life: Not a drug; laboratory lymphocyte effects unfold over 48–72 hours, and the hepatitis C viral load low point came months after treatment began (Kuenstner 2015).
Single vs split dosing: Effects are pursued through repeated short sessions rather than one large exposure; Knott reported loss of benefit above the 5–7% volume range (Hamblin 2017, a review).
Genetic polymorphisms: No variant guides dosing; G6PD deficiency is an inferred reason for caution.
Sex: Weight-based volume scales the dose; women have more vasovagal reactions during blood withdrawal, per a meta-analysis (Wu 2025); smaller first draws for women follow common practice.
Age: No age-specific protocol exists; older adults on anticoagulants face a higher risk of access-site bruising and bleeding.
Baseline biomarkers: Hemoglobin and platelet count determine whether repeated draws and heparin are tolerable.
Pre-existing conditions: All studied regimens targeted active disease (infection, arterial or heart disease), not prevention.

Discontinuation & Cycling

Short-term or lifelong: Historically a short course for acute illness; clinics offering longevity use add periodic maintenance sessions without evidence supporting either pattern.
Withdrawal effects: None reported; stopping sessions has no known rebound effect.
Tapering: Not applicable; there is no physiological dependence to taper.
Cycling: No study has tested whether intermittent courses maintain any effect; when heparin is used, breaks between courses limit cumulative heparin exposure and HIT risk.

Sourcing and Quality

Regulatory status of devices: No FDA-approved UV blood irradiation device was identified for this review; in 2025 FDA cited a maker of ozone/UV blood devices for lacking premarket approval (FDA warning letter).
Distinct from photopheresis: Extracorporeal photopheresis (UVA plus methoxsalen) is a different procedure approved through FDA premarket approval (PMA) for specific diseases (FDA PMA P860003); its approval does not extend to wellness UVBI.
Wavelength and device type: Devices use either UVC in a quartz chamber (Knott type) or UVA/visible light via catheter; the evidence for each differs and doses are not interchangeable.
Disposables and sterility: Quality markers are single-use, sterile, sealed kits opened in front of the client and no shared saline bottles.
Device names: Historical and trial devices include the Knott Hemo-Irradiator and AVIcure Hemo-modulator; catheter systems include UVLrx. No independent quality testing program was identified.
Practitioner credentials: Quality markers are supervision by a licensed physician and staff trained in venipuncture and emergency care.

Practical Considerations

Time to effect: Historical reports describe changes within minutes to days in acute infection; in the hepatitis C trial the viral load low point came about 8–9 months after starting (Kuenstner 2015).
Common pitfalls: Treating feeling better after a session as proof of effect, stacking ozone and intravenous vitamins, skipping medication review, and choosing clinics with reusable equipment.
Regulatory status: No FDA-approved UVBI device was identified; FDA has issued a warning letter to an ozone/UV device maker (FDA warning letter).
Cost and access: About $100–350 per session (currency not stated), usually in multi-session courses, mostly at wellness clinics and rarely covered by insurance, per a university outreach office with no stake in the procedure (McGill Office for Science and Society article).
Structural research gap: The original Knott technique is long out of patent, although newer devices are patented; device makers have funded only small trials or trials of related methods (Vasogen, AVIcure), and insurers rarely cover it, a source of under-study rather than evidence of inefficacy.

Interaction with Foundational Habits

Sleep: No direct interaction has been studied; no mechanism suggests UVBI disrupts or improves sleep. Sessions late in the day pose no known circadian issue because the light stays inside the body, not on the eyes.
Nutrition: Indirect: water and a salty snack beforehand reduce vasovagal reactions (Lewin 2023). Potentially blunting: large antioxidant doses near sessions may oppose the proposed oxidative signal; vitamins C and E reduced photosensitizer-driven ultraviolet red cell breakdown in a laboratory test (Eberlein-König 1997).
Exercise: No studied interaction. Common practice is to avoid heavy lifting with the punctured arm and strenuous exercise for several hours after a session to limit bruising and fainting.
Stress management: Indirect: fear and anxiety about needles raise vasovagal risk, per a meta-analysis (Wu 2025); slow breathing, distraction and reclining reduce it. No effect on cortisol has been measured.

Monitoring Protocol & Defining Success

Before a first course, baseline testing establishes whether repeated blood draws and heparin exposure are tolerable and provides a reference point for any disease marker the procedure is meant to change. It includes a complete blood count with platelets, bloodborne virus screening to document status before extracorporeal handling, and, if UVBI is used for chronic hepatitis C, viral load and liver enzymes.

Ongoing monitoring follows this cadence: platelet count before each session in the first two weeks of any course using heparin, then monthly during continued sessions; complete blood count every 3 months of regular use; viral screening repeated 3–6 months after a course; and disease-specific markers at 3 and 6 months. Success is defined by a change in a marker the procedure is expected to influence, not by how a session feels.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Platelet count	150–450 × 10⁹/L (standard reference range)	Safety: a fall signals heparin-induced thrombocytopenia (HIT)	HIT defined as a drop below 50% of baseline or below 100 × 10⁹/L plus a positive laboratory HIT test in a meta-analysis (Martel 2005); no fasting needed
Hemoglobin	Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL (standard reference range)	Safety: anemia limits repeated draws	Part of the complete blood count (CBC, a panel of blood cell counts); check before each course
Hepatitis B and C and HIV serology	Negative (standard reference range)	Safety: documents status before and after blood handling	HIV is human immunodeficiency virus; outbreaks with autologous blood procedures (Faustini 2005)
HCV RNA (viral load)	No established target for UVBI; track change from own baseline	Expected to change when treating hepatitis C	RNA is the viral genetic material; reported falls (Kuenstner 2015); same laboratory each time
ALT and AST	ALT about 7–56 U/L, AST about 10–40 U/L (standard reference range)	Expected to change when treating hepatitis C	ALT and AST are liver enzymes released by injured liver cells; fell 19.3% and 15.2% in the HCV trial (Kuenstner 2015); avoid hard exercise 24 hours before

Qualitative markers:

Bruising, pain or redness at the access site after each session
Lightheadedness or fainting during or after the draw
Frequency and duration of infections over the following months
Energy levels and exercise tolerance compared with the pre-course baseline
Any skin rash or sun sensitivity, especially with photosensitizing medications

Emerging Research

No ongoing registered trial: As of 10/30/2026, ClinicalTrials.gov lists no recruiting or active trial of ultraviolet blood irradiation. The evidence base for healthy adults is therefore unlikely to change from registered trials in the near term.
HemoModulator in HIV (NCT00858923): Phase 1, single-arm, 10 participants with untreated HIV, weekly sessions for 10 weeks; estimated completion 2009, status unknown, no results posted. A published viral-load fall would support antiviral claims; a null result would weaken them.
Endotracheal UVA in COVID-19 (coronavirus disease 2019) (NCT04572399): Completed 2020 with results: five ventilated patients had a 2.41-log (roughly 250-fold) fall in airway viral load by day 5, no control group (Rezaie 2021). It irradiated the airway, not blood, so it does not test UVBI.
Intravenous laser blood irradiation: Small trials of red or visible intravenous laser light continue; a 2025 systematic review notes small samples and non-standard dosing (Chang 2025). Larger trials could clarify whether intravascular light of any wavelength has clinical effects.
Dose-finding chemistry: Ultraviolet light oxidized albumin yet increased its antioxidant activity, and flash xenon lamps needed ten-fold lower doses than mercury lamps (Sozarukova 2023), a route toward individualized, safer dosing.
Evidence weakening direct-kill claims: A multi-wavelength intravenous device reduced bacteria in circulated sheep blood by only about 0.5 log (about threefold), with no effect from its ultraviolet component (Willmott 2023).

Conclusion

UV blood irradiation exposes a small share of a person’s own blood to ultraviolet light and returns it to the body. It began as a hospital treatment for severe infections before antibiotics, faded in the West while research continued in Russia and Germany, and is now sold mainly by wellness clinics to strengthen immunity and resilience.

For health-focused adults, the central fact is that no study has tested it in healthy people pursuing long-term health. The best human evidence comes from small trials in people with active infections, where adding the treatment to antibiotics appeared to speed recovery, but each trial studied a different infection and none was repeated. Signals in hepatitis C, leg artery disease and heart failure are weak, come from related but different treatments, or are contradicted, and the largest related trial found no clear benefit. Proposed effects on immune cells and antioxidant defenses come from laboratory and animal work.

The main risks come from the procedure rather than the light: bruising, fainting, vein irritation, bleeding in people taking medicines that slow clotting, and infection if equipment is reused. A quieter risk is using it instead of proven care for serious disease. No device approved by United States regulators for this use was found. Much supportive literature is old, lacks comparison groups or is written by device makers and practitioners who sell the treatment. The evidence base is thin, and the procedure’s value for long-term health remains unknown.

Top - Benefits - Risks - Protocol

UV Blood Irradiation for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Faster Clearance of Bacterial Infections When Added to Antibiotics

Low 🟩

Lower Viral Load in Chronic Hepatitis C

Longer Walking Distance in Intermittent Claudication

Fewer Heart Failure Events ⚠️ Conflicted

Speculative 🟨

Immune Recalibration and Antioxidant Up-Regulation

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Bloodborne Infection From Unsafe Blood Handling

Low 🟥

Venipuncture Reactions: Bruising, Fainting and Vein Inflammation

Delayed Effective Treatment of Serious Disease

Heparin-Related Bleeding and Heparin-Induced Thrombocytopenia

Flare of Systemic Lupus Erythematosus

Speculative 🟨

Oxidative Damage to Blood Proteins, Lipids and Lymphocytes

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion